We are particularly interested in acquiring and/or licensing pharmaceutical products for treating gastrointestinal (GI), infectious diseases and specialty hospital products.
We aim to continue our fast growth track of the last 20 years and M&A is a strategic pillar for achieving this.
The strategic fit of your products with our current portfolio as well as our well-established network and long-standing, comprehensive expertise in the areas necessary for the fast integration and further successful growth of your products will ensure your and our future success.